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Identity 
Other names: P2Y8 
HGNC (Hugo): P2RY8 
Location: Xp22.33 
Local order 
The P2RY8 gene is located at the pseudoautosomal 
region 1 (PAR1) of chromosome X and chromosome 
Y. 
Note 
ChrX: 1581465-1656037 base pairs (hg19) from pter 
(74573 bases).  
Orientation: minus strand.  
ChrY: 1531465-1606037 (hg19). 
DNA/RNA 
Description 
The P2RY8 gene is located on both chromosomes X 
and Y. It was discovered by Cantagrel and co- 
workers while investigating a pericentric inversion 
on the X chromosome, inv(X)(p22.3 q13.2), in a 
family with mental retardation. The gene is 
composed of 4 exons and the promoter region 
contains the regulatory transcription factor binding 
sites for CREB, POU3F1 and deltaCREB. 
Transcription 
The transcribed RNA has 4198 base-pairs and 
encodes a 359 amino acid protein. A second non-
encoding transcript exists (splice variant) that has 
407 base-pairs. 
Pseudogene 
Fusion gene: a 320-kb large interstitial deletion 
within the pseudoautosomal region 1 (PAR1) on 
chromosome X [del(X)(p22.33p22.33)] and 
chromosome Y [del(Y)(p11.32p11.32)] results in 
juxtaposition of the first non-encoding exon of 
P2RY8 to the CRLF2 coding region to form P2RY8-
CRLF2 fusion which leads to over-expression of 
full-length CRLF2. 
Schematic diagram of the human X chromosome indicating the location of the P2RY8 gene. 
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Protein 
Description 
The protein encoded by P2RY8 gene is composed of 
359-amino acids and belongs to the P2Y family of 
G-protein coupled receptors that are preferentially 
activated by adenosine and uridine nucleotides. 
There are eight mammalian P2Y receptors known to 
date (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, 
P2Y13 and P2Y14) and they are found in most 
human tissues. The specfic function of the P2RY8 
receptor remains uncharacterised. 
Expression 
P2RY8 is highly expressed in lymphocytes, with 
weaker expression in heart, kidney and lung 
(Cantagrel et al., 2004). Adundant expression of 
P2RY8 has been demonstrated in bone marrow 
CD34+ cells in leukaemic patients (Fujiwara et al., 
2007). However P2RY8 expression appears to be 
down-regulated during leucocyte differentiation: 
normal, mature peripheral blood leucocytes have 
been shown to have minimal expression, while an 
undifferentiated promyelocytic leukaemia cell line 
was shown to have moderate expression of P2RY8 
that was down-regulated with induction of 
granulocyte differentiation (Adrian et al., 2000). 
Similarly, P2RY8 expression decreases during the 
differentiation of monocytes to macrophages 
(Hohenhaus et al., 2013). 
Localisation 
Cell membrane. 
Function 
Using retroviral expression screening for 
transforming genes in biphenotypic acute leukaemia, 
P2RY8 has been confirmed to have oncogenic 
potential (Fujiwara et al., 2007). The P2RY8-CRLF2 
fusion is present in 5-7% of paediatric B-cell acute 
lymphoblastic leukaemia and > 50% of Down 
syndrome-associated acute lymphoblastic leukaemia 
(Mullighan et al., 2009; Russell et al., 2009; Cario et 
al., 2010; Hertzberg et al., 2010; Dyer et al., 2010) 
and has been identified as a poor prognostic factor 
associated with high risk disease with an increased 
risk of relapse (Cario et al., 2010; Ensor et al., 2011; 
Palmi et al., 2012; Attarbaschi et al., 2012; 
Yamashita et al., 2013). P2RY8-CRLF2 results in 
overexpression of full-length cytokine receptor-like 
factor 2 (CRLF2; also known as the thymic stromal 
lymphopoietin receptor), which together with IL7 
receptor alpha forms a heterodimeric complex that 
acts at the functional receptor for thymic stromal 
lymphopoietin (reviewed in Roll and Reuther, 2010).  
CRLF2 alterations are associated with the presence 
of activating mutations in the JAK genes JAK1 and 
JAK2 (Russell et al., 2009; Mullighan et al., 2009; 
Hertzberg et al., 2010; reviewed in Roll and Reuther, 
2010), as well as mutations of the lymphoid 
transcription factor gene IKZF1 (IKAROS) (Harvey 
et al., 2010).  
Although P2RY8-CRLF2 fusions have been 
confirmed as a clear clinical risk factor in paediatric 
ALL, their precise role in the leukemic process 
remains to be elucidated with studies supporting 
involvement in the cellular transformation process 
but suggesting they function as a secondary capacity 
in driving the entire leukemic process (Morak et al., 
2012). 
Implicated in 
B-acute lymphoblastic leukaemia (B-
ALL) and Down syndrome-
associated acute lymphoblastic 
leukaemia 
Disease 
As P2RY8-CRLF2 fusion in B-acute lymphoblastic 
leukaemia (B-ALL) and Down syndrome-associated 
acute lymphoblastic leukaemia (DS-ALL) 
(Mullighan et al., 2009; Russell et al., 2009; Cario et 
al., 2010; Hertzberg et al., 2010; Dyer et al., 2010). 
Prognosis 
Associated with increased relapse risk and overall 
inferior outcome (Cario et al., 2010; Ensor et al., 
2011; Palmi et al., 2012; Attarbaschi et al., 2012; 
Yamashita et al., 2013). 
Cytogenetics 
Rearrangements are typically G- and R-band cryptic. 
Hybrid/Mutated gene 
An interstitial deletion of the pseudoautosomal 
region 1 (PAR1) of either of the sex chromosomes 
results in juxtaposition of the first noncoding exon of 
the P2RY8 gene to the first exon of CRLF2, such that 
CRLF2 expression from this chimeric locus is driven 
by the P2RY8 promoter. 
Oncogenesis 
Refer to protein function above. 
Diffuse large B-cell lymphoma 
(DLBCL) 
Note 
Coding mutations in P2RY8. 
Prognosis 
Coding mutations were identified in 6 out of 55 
patients (11%) with DLBCL using massively 
parallel whole-exome sequencing.  
The impact of this mutation on prognosis remains 
unknown (Lohr et al., 2012). 
Oncogenesis 
The functional consequences of P2RY8 mutation in 
DLBCL remains to be determined. 
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